Starpharma Holdings Rated ‘Speculative Buy/4,’ Lead Dendrimer Product Stands At Forefront Of Global HIV/AIDS Prevention Strategies, According To Investrend Research Analyst Sharifzadeh In Initial ‘Benchmark’ Report
NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate)Starpharma Holdings Limited (OTC: SPHRY) (ASX: SPL) has been rated “Speculative Buy/4” by Investrend Research analyst Mohammad Sharifzadeh, CFA, PhD., in his initial “Benchmark” Report on the company.
“Starpharma’s major expense item is R&D expense which reflects the Company’s active strategy of staying as a leading entity in the dendrimer industry.”
Sharifzadeh is also lead analyst for Investrend’s nanotechnology sector research coverage commissioned by Cronus Capital Markets.
The full Starpharma report, including important disclosures and disclaimers, is at http://www.investrendresearch.com. In it the analyst stated:
“Starpharma Holdings Limited is an emerging company operating in an emerging industry. Starpharma’s business strategy is to use dendrimer-based nanotechnology to discover, develop and commercialize pharmaceuticals for serious human diseases.
“VivaGelTM is Starpharma’s lead dendrimer product. It is a gel-based microbicide with a nanotech active being developed to prevent sexually transmitted infections in women.
“VivaGel™ addresses markets with huge potentials. Starpharma’s VivaGel stands at the forefront of the global HIV/AIDS prevention strategies.
“VivaGel™ has received clearance from the U.S. FDA for human clinical trials and the company has already opened the site in the U.S. to recruit volunteers for the clinical trial of VivaGel™ for prevention of genital herpes.
“We agree with Starpharma’s management that acquisition of DNT results in valuable synergies including more U.S. presence, extensive IP portfolio, road to commercialization, and a more diversified product base.
“Starpharma has a healthy balance sheet. They have a strong cash position which can support their operating and R&D expenses should there be a shortfall in revenues. Starpharma has almost a debt free balance sheet with substantial equity which provides the company with the opportunity of external financing should the need arises.
“During the Fiscal Year 2006 Starpharma’s revenue from government sources was a total of A$6,422,066, almost five times the A$1,409,844 government related revenue in Fiscal year 2005.
“Starpharma’s major expense item is R&D expense which reflects the Company’s active strategy of staying as a leading entity in the dendrimer industry.
Starpharma’s loss per share decreased from 6.97 Australian Cents in FY05 to 5.69 Australian Cents in FY06.”
The full report, including important disclosures and disclaimers, is available at http://www.investrendresearch.com, and at the company’s InvestorPower Page at http://www.investrend.com/company/Company.asp?id= 1518&sPathParam=yes&sAlias=sphry.
(Due to the length of this URL, it may be necessary to copy and paste it into your Internet browser's URL address field. You may also need to remove an extra space in the URL if one exists.)
Investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.
Starpharma Holdings is enrolled in Investrend Research’s pioneering professional research program, which facilitates independent analysts to provide coverage for shareholders in companies that otherwise would have little or no analyst following. Enrollment fees for the “Benchmark” research platform are $26,800, which is being paid by Cronus Capital Markets, a “third party.” Analysts are paid in advance for their initial reports by Investrend Research to limit or eliminate pecuniary interests, and no one associated with the program may own or trade in the equities of companies under coverage.
Investrend subscribes to the “Standards of Practice for Research Providers” at http://www.firstresearchconsortium.com, and its research is enrolled for investor monitoring by the not-for-profit Shareholders Research Alliance, Inc. (http://www.shareholdersresearch.com).
Anyone interested in receiving alerts regarding Starpharma Holdings research should email email@example.com with “SPHRY” in the subject line.